Venlafaxine Extended Release in the Short-Term Treatment of Depressed and Anxious Primary Care Patients With Multisomatoform Disorder

Kroenke, Kurt; Messina, Nicholas; Benattia, I.; Graepel, Jay; Musgnung, Jeff

doi:10.4088/jcp.v67n0111

Cited by 77 publications

(25 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are strong indications in the research literature that awareness of an anxiety or depressive disorder may affect treatment decisions for pain patients. Effective treatments for pain in patients suffering from anxiety and depression have been noted [Kroenke et al, 2006]. In addition, treatment of depression is associated with decreases in reports of pain intensity and improvements in pain-related disability [Lin et al, 2003], suggesting that treating the psychiatric disorder may be an important component in the treatment of pain.…”

Section: Discussionmentioning

confidence: 99%

Relationships among pain, anxiety, and depression in primary care

et al. 2008

View full text Add to dashboard Cite

Pain, anxiety, and depression are commonly seen in primary care patients and there is considerable evidence that these experiences are related. This study examined associations between symptoms of pain and symptoms and diagnoses of anxiety and depression in primary care patients. Results indicate that primary care patients who endorse symptoms of muscle pain, headache, or stomach pain are approximately 2.5-10 times more likely to screen positively for panic disorder, generalized anxiety disorder, or major depressive disorder. Endorsement of pain symptoms was also significantly associated with confirmed diagnoses of several of the anxiety disorders and/or major depression, with odds ratios ranging from approximately 3 to 9 for the diagnoses. Patients with an anxiety or depressive disorder also reported greater interference from pain. Similarly, patients endorsing pain symptoms reported lower mental health functioning and higher scores on severity measures of depression, social anxiety, and posttraumatic stress disorder. Mediation analyses indicated that depression mediated some, but not all of the relationships between anxiety and pain. Overall, these results reveal an association between reports of pain symptoms and not only depression, but also anxiety. An awareness of these relationships may be particularly important in primary care settings where a patient who presents with reports of pain may have an undiagnosed anxiety or depressive disorder.

show abstract

Section: Discussionmentioning

confidence: 99%

Relationships among pain, anxiety, and depression in primary care

et al. 2008

View full text Add to dashboard Cite

show abstract

“…These methods aim at economically detecting mental disorders and have been used and validated in a variety of studies [8,[13][14][15][16][17][18][19][20]. Validity, classification characteristics and responsiveness to change have been reported by these studies.…”

Section: Introductionmentioning

confidence: 99%

Classification characteristics of the Patient Health Questionnaire-15 for screening somatoform disorders in a primary care setting

Körber

Frieser

Steinbrecher

et al. 2011

Journal of Psychosomatic Research

114

View full text Add to dashboard Cite

“…Patients with GAD often present for treatment with a variety of somatic complaints rather than psychological symptoms [Kroenke et al, 2006;Schulz et al, 2005]. These patients have significantly more frequent and severe somatic symptoms associated with cardiovascular, headache, muscular, and gastrointestinal distress than matched controls [Hoehn-Saric, 1998].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms

et al. 2008

View full text Add to dashboard Cite

Anxiety disorders often are accompanied by painful physical symptoms. This report assessed the effectiveness of duloxetine in improving anxiety symptoms, pain severity, and patient functioning in adults diagnosed with generalized anxiety disorder (GAD), who presented with clinically significant pain symptoms. Data were pooled from two multicenter, randomized, double-blind, placebo-controlled clinical studies evaluating the efficacy of duloxetine 60-120 mg once daily compared with placebo in the treatment of GAD. The primary patient population for these analyses was patients with baseline Visual Analog Scale (VAS) overall pain severity score > or =30. Of the 798 randomized patients that had baseline VAS scores, approximately 44.4% of GAD patients were identified as having baseline VAS overall pain severity score > or =30 (duloxetine N=208, placebo N=146). Duloxetine-treated patients had significantly greater improvement compared with placebo-treated patients on anxiety symptoms (measured by Hamilton Anxiety Scale total score), on patient functioning (measured by the Sheehan Disability Scale Global Functional Impairment Score and across all Sheehan Disability Scale domains), and on all VAS pain items. Patients achieving remission at endpoint, and patients with lower scores on the Clinical Global Impression of Improvement and Patient Global Impression of Improvement scales had greater improvement in VAS pain severity scores. These results suggest that in patients with GAD who present with clinically significant pain symptoms, duloxetine is effective in reducing anxiety symptoms, pain severity, and in improving patient functioning.

show abstract

Venlafaxine Extended Release in the Short-Term Treatment of Depressed and Anxious Primary Care Patients With Multisomatoform Disorder

Cited by 77 publications

References 0 publications

Relationships among pain, anxiety, and depression in primary care

Relationships among pain, anxiety, and depression in primary care

Classification characteristics of the Patient Health Questionnaire-15 for screening somatoform disorders in a primary care setting

Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms

Contact Info

Product

Resources

About